Article
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.
Frontiers in immunology - 1 Jan 2023
Cruz David, Rodríguez-Romanos Rocío, González-Bartulos Marta, García-Cadenas Irene, de la Cámara Rafael, Heras Inmaculada, Buño Ismael, Santos Nazly, Lloveras Natàlia, Velarde Pilar, Tuset Esperanza, Martínez Carmen, González Marcos, Sanz Guillermo F, Ferrá Christelle, Sampol Antonia, Coll Rosa, Pérez-Simón Jose A, López-Jiménez Javier, Jurado Manuel, Gallardo David
Abstract excerpt
Introduction: The association of polymorphisms in molecules involved in the immune response (checkpoint inhibitors) with the clinical outcome after allogeneic transplantation (alloHSCT) has been described. Lymphocyte Activation 3 (LAG3) is a surface protein that plays a regulatory role in immunity as an inhibitory immune checkpoint molecule. Methods: To determine its role in the alloHSCT setting, we analyzed 797...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
